Best Diversified Pharmaceuticals Companies in Canada
The 44 best Diversified Pharmaceuticals companies in Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Merus Labs.
- Data Bridge Market Research
- The Business Research Company
Ranked: Best Diversified Pharmaceuticals companies in Canada
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Chemokine Therapeutics Developer of chemokine therapies | $5M | — | — | Hassan Salari Founder & President | Funding Raised | — | 16 patents Therapeutic chemokine and cyclic peptide engineering for angiogenesis and hematopoietic modulation | — |
| 2 | ApoPharma Canadian pharma company focused on treatments for hematological, neurodegenerative and immune diseases | — | — | 218 | — | Unfunded | — | — | — |
| 3 | Aurex Laboratories R&D company focused on manufacturing of drugs for multiple therapeutic areas | — | — | 30 | Ranga Aravapalli CEO | Acquired | — | — | — |
| 4 | Biovail R&D company focused on manufacturing of drugs for multiple therapeutic areas | — | — | 1,368 | Mahmood Kahn Co-Founder | Acquired | — | 2 patents Controlled-release oral dosage formulations of bupropion hydrochloride | — |
| 5 | Celverum Developer of pharmaceutical preparations for cancer, immunological, inflammatory, and auto-immune diseases | — | — | — | David Conrad CEO | Funding Raised | — | 14 patents Non-replicating virus-like particle platforms for vaccine and therapeutic delivery | — |
| 6 | Cyclenium Pharma Canadian, preclinical-stage biopharma developing macrocycle drugs for oncology, infections, and pain | — | — | 5 | Mark Peterson Co-Founder & COO | Acquired | — | 21 patents Macrocyclic drug‑like compound libraries for pharmaceutical discovery and development | — |
| 7 | Designed Biologics Small peptides with designed targeting properties for the treatment of human diseases and diagnostics | — | — | — | Frank Dehne Co-Founder & President | Unfunded | — | — | — |
| 8 | Exzell Pharma R&D company focused on manufacturing of drugs and ointment for multiple therapeutic uses | — | — | 5 | — | Acquired | — | — | — |
Top 12 Diversified Pharmaceuticals companies in Canada
#1
Public · Toronto, Ontario · founded 1983 · 17 employees$7.6Mraised▾
Arch Biopartners business model is based on working closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors. Arch has established a diverse portfolio that includes MetaMx (synthetic peptides that target and attach to BTICs and invasive glioma cells), which targets illusive brain tumor-initiating cells; AB569 (inhalable small molecule), a potential new treatment for Pseudomonas aeruginosa pulmonary infections; and, Metablok, a potential treatment for sepsis and cancer metastasis. MetaMx and AB569 are both on track to enter human clinical trials in late 2016 or early 2017.
- Mar 2026Post IPO$431.8K
- Nov 2025Post IPO$427.1K
- Mar 2025Post IPO$261.7K
- Mar 2025Post IPO$241.9K
#2
Public · Vancouver, British Columbia · founded 2015 · 1 employees$12.8Mraised▾
Algernon Pharmaceuticals is a developer of small molecules for chronic kidney disease and inflammatory bowel diseases. The company is using a drug repurposing strategy to discover drugs. The lead candidate, NP-135 is an antifibrotic compound being investigated for NASH (phase 1). Other molecules are in phase 1 trials for CKD and IBD.
- Nov 2025Post IPO$607.7K
- May 2025Post IPO$554.6K
- Jul 2024Post IPO$299.4K
- Apr 2024Post IPO$12.6K
#3
Series A · Ottawa, Ontario · founded 2011 · 21 employees$15.6Mraised▾
Provider of biologic therapeutics for addressing obesity and metabolic disorders through the development of next-generation GPCRs. Using its proprietary PROcisionX™ platform, the company rapidly discovers and optimizes biologic molecules, advancing precision therapies from target identification to lead candidates in months.
- May 2025Series A$774.4K
- Dec 2024Series A$531K
- Jul 2024Series A$6.8M
- Mar 2023Series A$9.9M
#4
Public · Vancouver, British Columbia · founded 2006 · 11 employees$7.4Mraised▾
Developer of therapeutics for the treatment of skincare. The company is developing anti-aging and anti-wrinkle molecule, TFC-1326, as GlycoProteMim to preserve and restore youthful skin and reverse aging.
- Apr 2025Post IPO$2.2M
- Apr 2024Post IPO$97.8K
- Jul 2019Post IPO$1.1M
- Feb 2019Post IPO$1.8M
#5
Public · Montreal, Quebec · founded 2004 · 98 employees$122.8Mraised▾
Manufacturer of pharmaceutical drugs catering to rheumatology, immunology, and oncology among others
- Sep 2022Conventional Debt$55M
- Mar 2020Post IPO$400K
- Oct 2018Post IPO$62M
- Mar 2015Convertible Debt$1.2M
#6
Acquired · Quebec City, Quebec · founded 2003 · 121 employees$25Mraised▾
Valeo Pharma is a Canadian specialty pharma company. Their most important product is the Synacthen Depot (1mg/mL), which is a synthetic ACTH product (Tetracosactide Zinc Injection). This has been approved for 17 indications in Canada. They also have a JV partnership with Valeant pharma for Baclofen and Vancomycin.
- Aug 2023Post IPO$2.9M
- Nov 2021Post IPO$15M
- Jul 2020Post IPO$1.7M
- Nov 2019Post IPO$4M
#7
Acquired · Toronto, Ontario · founded 2009 · 22 employees$161.7Mraised▾
Merus Labs corporate growth strategy is driven by a product acquisition plan which employs an opportunistic approach to source product acquisition candidates. Its product portfolio includes Sintrom® (acenocoumarol), an anticoagulant indicated to treat and prevent thromboembolic diseases; Enablex® (darifenacin) to treat overactive bladder syndrom; Salagen® (Pilocarpine hydrochloride, oral tablet, 5mg) to manage dry mouth associated with radiation therapy (head and neck); Vancocin® (vancomycin) capsules to treat infections caused by bacteria such as C.difficile in the gastrointestinal tract.
- Mar 2016Post IPO$20M
- Apr 2015Post IPO$60M
- Mar 2014Post IPO$20M
- Jun 2013Post IPO$4.6M
#8
Public · Vancouver, British Columbia · founded 1981 · 18 employees$23Mraised▾
InMed Pharmaceuticals is a drug discovery and development company uniquely focused on the therapeutic potential of cannabinoids. Its drug pipeline includes INM-750, for the treatment of Epidermolysis Bullosa ( inherited connective tissue diseases) (preclinical) and INM-085, for the treatment of Glaucoma (preclinical).
- Dec 2022Post IPO$6M
- Sep 2022Post IPO—
- Jun 2022Post IPO$5M
- Jun 2021Post IPO—
#9
Deadpooled · Halifax, Nova Scotia · founded 2000 · 63 employees$39.6Mraised▾
Developer of vaccines for the treatment of different cancers and infectious diseases
- Aug 2020Grant (prize money)—
- May 2020Post IPO$3.6M
- May 2020Post IPO$17.8M
- Mar 2019Grant (prize money)—
#10
Acquired · Toronto, Ontario · founded 2010 · 11 employees$11.6Mraised▾
Antibe is focused on diseases characterized by inflammation, pain and/or vascular dysfunction. Its drug design approach is to create new drugs by improving existing, proven drugs. They have a technology platform that enables them to chemically link an existing drug to a hydrogen sulfide-releasing moiety. Acting as neuromodulators, immunomodulators, and vasodilators, gaseous mediators such as H2S regulate fundamental cellular processes. Antibe believes that H2S has tremendous therapeutic potential.
- Aug 2019Post IPO$283.3K
- Dec 2018Post IPO$1.6M
- Dec 2016Post IPO$2.4M
- Jun 2016Post IPO$486.5K
#11
Funding Raised · Mississauga, Ontario · founded 2008 · 225 employees$24.2Mraised▾
Therapure Biopharma focuses on manufacturing complex biologics and on developing, manufacturing, and selling its blood and plasma-related therapeutic products. It operates through three divisions: Therapure Biomanufacturing (Mammalian cell line based CDMO), Therapure Biologics (Plasma-derived products), and Therapure Innovations (Proprietary drug development). It provides contract development and manufacturing services for integrated biologics and also offers drug discovery, research, and development services. The company also focuses on the development of a portfolio of its own plasma-derived protein therapeutics through its technology, PlasmaCap EBA (for efficient capture of plasma proteins at high yields and purities). Therapure Innovations' lead candidates TBI 302 (liver cancer) and TBI 304H (anemia) are undergoing phase I trials while TBI 301 (Hep C) is in the discovery stage. The company is funded by the Catalyst Capital Group since its inception. The company's CDMO business and certain rights to their plasma products and technology for the Chinese market were acquired by a JV between 3SBio and CPE funds.
- Aug 2015Conventional Debt$20M
- Apr 2010Grant (prize money)$4.2M
#12
Funding Raised · Sherbrooke, Quebec · founded 2012 · 29 employees$10.9Mraised▾
Immune Biosolutions company is a Canada-based early-stage biopharma developing antibody therapeutics as well as polyclonal and recombinant IgY antibodies services. Their first business focus is on cancers and gastrointestinal diseases that can be treated by orally-administered immunotherapy. Their 2nd area of focus is on disease areas involving GPCRs and other membrane proteins. They also provide their clients with services for antibody development, engineering, and tailoring. Their therapeutic candidates have not been disclosed as on Oct.2017
- Mar 2021Grant (prize money)$10.8M
- Apr 2017Grant (prize money)$100K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Diversified Pharmaceuticals coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.